CrownBio provides an integrated platform for preclinical drug development and expert consultation that will enable your clear next-step decision

"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

Inflammatory Bowel Disease (IBD)

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory condition that is thought to result from an inappropriate host response to the local microenvironment resulting in the activation of an immune response and inflammation. Genetic, immune, and environmental factors may all play a role in the development of disease. Preclinical models have been established to study IBD and are powerful tools not only to dissect the mechanism of disease pathology, but to determine efficacy and response to treatment. These models will speed selection of your next qualified Crohn’s disease and Ulcerative Colitis lead agent.

Gut Epithelia/Barrier Defect Mouse Model – DSS Induced Colitis

Dextran sulfate sodium (DSS) is a sulfated polysaccharide with variable molecular weights. Administration of DSS in the drinking water causes activation of neutrophils and macrophages that result in a compromised mucosal barrier function.

Innate and Regulatory Cell Mediated Mouse Model –  T Cell Transfer

CD4+CD45RBhi cells are isolated from spleens of BALB/c mice and transferred to RAG1-/- or SCID recipients. Peak clinical disease observations usually occur 6–8 weeks post-transfer.

Major Endpoints

  • Weight loss
  • Diarrhea
  • Colon weight/length
  • Histopathological assessment